Numerous novel therapies including PPAR agonists, anti-fibrotic therapies and agents targeting inflammation, oxidative stress and the gut-liver axis are currently in development, with the aim of targeting key processes in the progression of NASH and HCC. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.